Metabolic

Survodutide

Acylated peptide · GLP-1/glucagon dual agonist · Synthetic

FDA · PHASE 2/3 TRIALS

Half-life

~5.5 days

Long

minsdays

Route

SubQ injection

Evidence

Clinical trial data

Risk

Standard

Overview

Known for

Dual GLP-1/Glucagon agonist (different mechanism to tirzepatide which is GLP-1/GIP). Being studied for obesity and NASH. The glucagon component may help with liver fat specifically.

Mechanism

Dual GLP-1 + glucagon agonist — similar to retatrutide minus GIP. Glucagon adds liver fat reduction + thermogenesis.

Key facts

Format
Lyophilized powder
Mechanism targets
Classification
Active
Supply & nature
ExogenousExogenous
FDA category
Phase 2/3 trials

Evidence & standing

Evidence base
Clinical trial data
Risk level
Standard
Clinical phase
Phase 3
Best studies
4 references
  • Blüher et al. (2024) Phase 2 Trial. NEJM 391:1616-26. DOI: 10.1056/NEJMoa2403838
  • Phase 3 SYNCHRONIZE program ongoing (Boehringer Ingelheim)
  • NOT YET FDA APPROVED
  • ClinicalTrials.gov: NCT06058364

Dosage & protocol

Typical dose
0.5mg
Research range
0.3–6 mg
Cycle
Weekly injection
Onset
21 days first effects
Full effect
168 days
Half-life
~5-6d
~5-6 days
Protocol

Early research: titrate from 0.5mg → up to 4.8-6mg weekly. Protocol still being established in trials.

Time to effects

EARLY: 2-4 weeks

FULL: 24+ weeks

Limited human data. Expected timeline similar to other GLP-1 agonists but with potentially faster liver fat reduction due to glucagon component.

Week 2-4: Appetite suppression, early weight loss.

Week 12-24: Significant fat loss and metabolic improvements.

Minimum commitment: 12 weeks to assess.

Recommended vial
  • 10mg (only size)

At 2-4mg/wk, 10mg lasts 2.5-5 weeks ✓. Fits within shelf life at most doses.

Reference figures only

Dosing reflects published laboratory protocols and is not guidance for use in any living subject.

Safety

Reversibility
Unknown
Side effects

Nausea (38%), diarrhoea (21%), vomiting (18%), decreased appetite (11%)

Interactions

Expected similar to GLP-1 class. Glucagon component may affect hepatic drug metabolism.

Do not combine
CagrilintideCagrilintide Cagrilintide 5mg + Semaglutide 5mg (Blend)Cagrilintide 5mg + Semaglutide 5mg (Blend) RetatrutideRetatrutide SemaglutideSemaglutide TirzepatideTirzepatide

Handle with research caution

  • Do NOT combine with other GLP-1 agonists (Tirzepatide, Retatrutide, Semaglutide)
  • Same-class stacking = dangerous GI and metabolic side effects

Storage & handling

Lyophilised
12–24 months
2–8°C
Reconstituted
4–6 weeks
2–8°C

Videos & talks

Independent educational content from researchers, clinicians and science communicators — not affiliated with Pepnerd.

Educational resources only. Videos are independent third-party content. Pepnerd is not affiliated with these creators and does not endorse or make claims based on their content. All products are for in-vitro research.